Only original pharmaceutical products that passed 3 stages of clinical trials.
Our products are produced on GMP or state licensed factories.
10% CRYPTO DISCOUNT
10% discount for paying in BTC or other cryptocurrency.
PAYMENT BY CARD
Convenient Payment by Visa or MasterCard.
Guaranteed delivery times and clear Reshipment & Refund Rules.
Different shipping methods and same or next day shipping.
DELTARAN ® (Delta-Sleep-Inducing Peptide | DSIP)
Deltaran is a representative of the class of neuroprotectors. It has a powerful antioxidant, stress-protective, and antidepressant effect. It protects neurons from the destruction by toxic, infectious, and other damaging agents, and also prevents the death of nerve cells because of stress.
Deltaran (DSIP) is based on a synthetic nonapeptide – an analog of one of the most important natural endogenous peptides – discovered in 1977 by Swiss scientists Monnier M. and Schoenenberg G.A. – the regulatory delta-sleep peptide (DSIP: delta-sleep-inducing peptide) with a stabilizing effect on the cell homeostasis. DSIP in free and bound form is present in peripheral organs, tissues and body fluids, hypophysis, hypothalamus, and in the limbic system of the brain. One of the most impressive features of its wide multifunctional action is its pronounced stress-protective and adaptogenic activity.
The peptide-based Deltaran drug was originally developed as an anti-alcohol medication. The development was carried out in the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry together with the Pharmacology Institute of the Russian Academy of Medical Sciences in the 1980s. After conducting experimental and clinical studies, the drug Deltaran was registered by the Ministry of Health of the Russian Federation in July 1998.
The main mechanism of action of the drug is the compensation for the deficiency of DSIP, which protects neurons from the destruction, resulting from psycho-emotional or systemic stress, toxic effects, or aging. Protecting the central nervous system from damaging effects. Buy Delta-sleep-inducing peptide to radically change the course of a large number of diseases in a favorable direction, to increase the effectiveness of standard medicines, and to prevent the development of complications. In clinical trials and testing, DSIP has shown a number of positive effects:
- Pronounced stress-protective and adaptogenic effect;
- Increased body resistance to adverse stress factors and pathological conditions of different etiologies;
- Antidepressant and anticonvulsant effects;
- Normalization of sleep;
- Antitoxic properties;
- Improving mental and physical performance;
- Limitation of vegetative and cardiovascular disorders in case of stress;
- Reduction of the primary pathological craving for alcohol and drugs, and manifestations of alcohol withdrawal;
- Complex therapy for neuroborreliosis, multiple sclerosis, cerebral palsy. [Biomedical Journal Medline.ru (2001)]
Produced by State Research Institute of High Purity Preparations, Russia.
Also, check Stresam!
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease. See more
The use of Deltaran makes it possible to compensate for the deficiency of endogenous neuroprotectors in the body, which ensures unimpaired functioning of the central nervous system in extreme situations.
Dosage and administration
The content of 1 ampoule of Deltaran is dissolved in 0.5 ml of boiled water of room temperature (10–12 drops or half a pipette) immediately before use and is pipetted into both nasal passages with an interval of 15–20 minutes. After an intranasal administration, the drug reaches the thalamic nuclei in 1.5–2 minutes. The stabilizing effect develops, depending on the level of endogenous peptides, within from 3 minutes to 1.5 hours.
The resulting solution is utilized in full and cannot be stored. The pipette is washed thoroughly with boiled water after use.
1–3 ampoules per day are used for 5–10 days for the prevention and treatment of a disease.
For detailed information on the drug administration please refer to the description.
Store in a dark place, at a temperature from 2°C (35.6°F) to 15°C (59°F).
The drug does not have a sedative action.
Adequate foreign analogs do not exist. Ciba-Gelgy Acea 1024 drug has a narrower spectrum of action, is not a direct derivative of DSIP, and contains substances that are alien to the human body, thus it has a number of side effects, including allergenic reactions. Hoffman La Roshe (AG Clinalfa) DSIP Clinalfa drug has a narrower scope (narcology and sleep disorders), its method of use (intravenous) is less convenient, in addition, it is several times more expensive than Deltaran.
Federal State Unitary Enterprise “State Research Institute of High Purity Preparations” of the Federal Medical-Biological Agency of Russia (FGUP “Gos. NII OChB” FMBA of Russia), Russia.
- Schoenenberg, Monnier (1977) Characterization of a delta-electroencephalogram (-sleep) -inducing peptide. https://www.ncbi.nlm.nih.gov/pubmed/265572
- Sudakov et al (1983) Delta-sleep-inducing peptide (DSIP) as a factor facilitating animals’ resistance to acute emotional stress. https://www.ncbi.nlm.nih.gov/pubmed/ 6687936
- Schoenenberg (1984) Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). https://www.ncbi.nlm.nih.gov/pubmed/6548966
- Graf, Kastin (1984) Delta-sleep-inducing peptide (DSIP): a review. https://www.ncbi.nlm.nih.gov/pubmed/6145137
- Graf, Kastin (1986) Delta-sleep-inducing peptide (DSIP): an update. https://www.ncbi.nlm.nih.gov/pubmed/3550726
- Westrin (1998) High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder. https://www.ncbi.nlm.nih.gov/pubmed/9606527
- Biomedical Journal Medline.ru (2001) https://www.medline.ru/public/art/tom2/art16e.phtml
- Khvatova et al (2003) Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. https://www.ncbi.nlm.nih.gov/pubmed/12668217
- Popovich et al (2003) Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. https://www.ncbi.nlm.nih.gov/pubmed/12782416
- Konorova et al (2006) Deltaran prevents an adverse effect of emotional stress on the course of cerebral ischemia in low-resistant animals. https://www.ncbi.nlm.nih.gov/pubmed/17181053
- Koplik et al (2008) Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection. https://www.ncbi.nlm.nih.gov/pubmed/18975104
- Grigorchuk, Umriukhin (2012) Neuronal activity in the dorsal hippocampus after lateral hypothalamus stimulation: effects of delta-sleep-inducing peptide. https://www.ncbi.nlm.nih.gov/pubmed/23113238
- Kutilin (2014) Effect of delta sleep-inducing peptide on the expression of antioxidant enzyme genes in the brain and blood of rats during physiological aging. https://www.ncbi.nlm.nih.gov/pubmed/25257425
- Banks (2015) Peptides and the blood-brain barrier. https://www.ncbi.nlm.nih.gov/pubmed/25805003
- Bobyntsev et al (2016) Effect of Delta Sleep-Inducing Peptide on Functional State of Hepatocytes in Rats During Restraint Stress. https://www.ncbi.nlm.nih.gov/pubmed/26902351
Based on Reviews
You will now receive regular updates from us!